


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1.-3. (Canceled).
4. (Previously presented) A pharmaceutical composition comprising
- (i) an effective amount of a compound of the formula:



where

each X independently is O, S, or NR₂;

R₂ is selected from the group consisting of cyano, nitro, hydrogen, C₁-C₄ alkyl, hydroxy, and C₁-C₄ alkoxy;

D is a direct bond or C₁-C₈ alkyl or alkenyl;

R is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;

or a pharmaceutically acceptable salt, ester, or solvate thereof;

(ii) an additional neurotrophic factor; and


(iii) a pharmaceutically acceptable carrier.

5. (Previously Presented) The pharmaceutical composition of claim 4, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.

6.-65. (Canceled).

66. (Previously presented) A pharmaceutical composition comprising

(i) an effective amount of a compound of the formula:



where

each X independently is O, S, or NR₂;

R₂ is selected from the group consisting of cyano, nitro, hydrogen, C₁-C₄ alkyl, hydroxy, and C₁-C₄ alkoxy;

D is a direct bond or C₁-C₈ alkyl or alkenyl;

R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;

wherein when both X substituents are O and D is a bond, R is not phenyl;

wherein when one X is O and the other is S and D is a bond, then R is not phenyl;

wherein when both X substituents are O and R is H, D is not C₁-C₈ alkyl;

or a pharmaceutically acceptable salt, ester, or solvate thereof;


(ii) an additional neurotrophic factor other than said compound; and

(iii) a pharmaceutically acceptable carrier.

67.-68. (Canceled).

69. (New) The pharmaceutical composition of claim 66, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.

70. (New) A method of making a pharmaceutical composition comprising, introducing, in a pharmaceutically acceptable carrier, (i) an effective amount of a compound of the formula:



where

each X independently is O, S, or NR₂;

R₂ is selected from the group consisting of cyano, nitro, hydrogen, C₁-C₄ alkyl, hydroxy, and C₁-C₄ alkoxy;

D is a direct bond or C₁-C₈ alkyl or alkenyl;

R is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;


or a pharmaceutically acceptable salt, ester, or solvate thereof; and

(ii) an additional neurotrophic factor.

71. (New) The method of claim 70, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor, acidic fibroblast

growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.

72. (New) A pharmaceutical composition comprising, introducing, in a



pharmaceutically acceptable carrier, (i) an effective amount of a compound of the formula:

where

each X independently is O, S, or NR₂;

R₂ is selected from the group consisting of cyano, nitro, hydrogen, C₁-C₄ alkyl, hydroxy, and C₁-C₄ alkoxy;

D is a direct bond or C₁-C₈ alkyl or alkenyl;

R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;

wherein when both X substituents are O and D is a bond, R is not phenyl;

wherein when one X is O and the other is S and D is a bond, then R is not phenyl;

wherein when both X substituents are O and R is H, D is not C₁-C₈ alkyl;
or a pharmaceutically acceptable salt, ester, or solvate thereof; and

(ii) an additional neurotrophic factor other than said compound.

73. (New) The pharmaceutical composition of claim 72, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotrophin-3, and neurotrophin-4/5.